Traneurocin (developmental code name NA-831), also known as cycloprolylglycine (CPG), is a racetam-like drug which is under development for the treatment of COVID-19, Alzheimer's disease, fragile X syndrome, Rett syndrome, major depressive disorder, and other neurological disorders.

[6][7] However, it has been described as acting as a positive allosteric modulator of the AMPA receptor and has been found to increase brain-derived neurotrophic factor (BDNF) levels.

[13][4] It is known to be an endogenous compound present at micromolar concentrations in the rat brain and readily crosses the blood–brain barrier.

[1][4] Chemically, traneurocin is a synthetic cyclized dipeptide composed of the amino acids glycine and proline.

[2] Traneurocin was first developed, under the name cycloprolylglycine (CPG), in Russia in 1991 as a drug related structurally and pharmacologically to piracetam.